杨沛然，博士生导师，本科、硕士、博士均毕业于英国剑桥大学，曾在美国哈佛医学院进行研究工作，开展肺动脉高压First-in-class新药研究并推动其转化，曾获得英国药理学会奖项。
      院校引进人才，2021年加入中国医学科学院基础医学研究所，呼吸和共病全国重点实验室，主持国家级青年人才项目、国家科技重大专项青年科学家项目、国家自然科学基金项目等。

杨沛然博士的研究方向是聚焦肺血管病变的呼吸疾病和共病研究，基于临床队列研究，结合多组学技术和特色体内外模型，解析不同类型肺动脉高压和呼吸共病的发生发展机制，探究肺血管病变在多种呼吸疾病中的作用，挖掘治疗靶点并开发新型疗法。作为第一或共同通讯作者（含共同）在Circulation, Sci Transl Med, Lancet RHWP等杂志发表论文，共发表SCI论文70余篇，被引2600余次，研究成果纳入相关领域指南。

1．Wang Y, Guo Z, Ma X, Xu Q, Li D, Yang J, Lu X, Yang P*, Zhang H*, Zhao H*, Wang C*. Integrated transcriptome and metabolome analysis reveals the therapeutic mechanism of Huang-Qi-Si-Wu-Tang in experimental pulmonary arterial hypertension. Phytomedicine. 2025 145:157058.

2．Li X^#, Ma S^#, Wang Q^#, Li Y^#, Ji X, Liu J, Ma J, Wang Y, Zhang Z, Zhang H, Chen H, Xi L, Zhang Y, Xie W, Sun L, Fu Z, Yang P*, Wang C*, Zhai Z*. A new integrative analysis of histopathology and single cell RNA-seq reveals the CCL5 mediated T and NK cell interaction with vascular cells in idiopathic pulmonary arterial hypertension. J Transl Med. 2024 22(1):502.

3．Weng H^#, Li H^#, Zhang Z^#, Zhang Y, Xi L, Zhang D, Deng C, Wang D, Chen R, Chen G, Tang S, Zuo X, Yang P*, Zhai Z*, Wang C. Association between uric acid and risk of venous thromboembolism in East Asian populations: a cohort and Mendelian randomization study. Lancet Reg Health West Pac. 2023 39:100848.

4．Liu J, Xu F, Zhang Z, Zhang Y, Zhen K, Lei J, Wang D, Yang P*, Zhai Z*. Comorbidities and high in-hospital mortality of cancer-associated pulmonary embolism: findings from a real-world registry study. Chin Med J (Engl). 2023 136(16):2005-2007.

5．Zhang Z, Cao Z, Hou L, Song M, Zhou Y, Chen Y, Hu H, Hou Y, Liu Y, Li B, Song X, Ge W, Li B, Jiang X, Yang J, Song D, Zhang X, Pang J, Zhang T, Zhang H, Yang P*, Wang J*, Wang C*. Adenovirus-mediated Over-Expression of FcγRIIB Attenuates Pulmonary Inflammation and Fibrosis. Am J Respir Cell Mol Biol. 2023 68(2):213-227.

6．Chen Y, Song M, Li Z, Hou L, Zhang H, Zhang Z, Hu H, Jiang X, Yang J, Zou X, Pang J, Zhang T, Yang P*, Wang J*, Wang C*. FcεRI deficiency alleviates silica-induced pulmonary inflammation and fibrosis. Ecotoxicol Environ Saf. 2022 244:114043.

7．Yang P, Bocobo GA, Yu PB. Sotatercept for Pulmonary Arterial Hypertension. N Engl J Med 2021 385(1):92-93.

8．Yung LM^#, Yang P^#, Joshi S, Augur ZM, Kim SSJ, Bocobo GA, Dinter T, Troncone L, Chen PS, McNeil ME, Southwood M, Poli de Frias S, Knopf J, Rosas IO, Sako D, Pearsall RS, Quisel JD, Li G, Kumar R, Yu PB. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020 12(543):eaaz5660. (C100, R)

9．Yang P^#, Read C^#, Kuc RE, Nyimanu D, Williams TL, Crosby A, Buonincontri G, Southwood M, Sawiak SJ, Morrell NW, Davenport AP, Maguire JJ. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019 176(9):1206-1221. (R)

10．Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ*, Davenport AP*. Elabela/Toddler Is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation. 2017 135(12):1160-1173. (C100, ESI, R)